文献速递垂体与肾上腺疾病

米托坦联合局部区域治疗用于低肿瘤负荷转移性肾上腺皮质癌

Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该回顾性研究纳入79例IVA期肾上腺皮质癌患者,评估米托坦联合局部区域治疗(LRT)与单用米托坦的疗效。结果支持欧洲和法国指南推荐米托坦联合LRT作为低肿瘤负荷IVA期患者的一线治疗。

要点

  • 米托坦联合LRT较单用米托坦显著延长PFS1、PFS2和OS。
  • 结果支持指南推荐米托坦联合LRT作为低肿瘤负荷IVA期ACC一线治疗。

核心结论

  • 在低肿瘤负荷IVA期肾上腺皮质癌患者中,米托坦联合局部区域治疗较单用米托坦显著改善生存结局。
  • 研究结果支持欧洲和法国指南推荐米托坦联合LRT作为该人群的一线治疗。

研究设计与样本

  • 回顾性图表审查,纳入2003至2018年单中心接受米托坦治疗的IVA期ACC且受累器官≤2个的患者。
  • 共纳入79例患者,48例(61%)为女性,IVA期诊断时中位年龄49.8岁(IQR 38.8-60.0岁)。

主要发现

  • 转移部位主要为肺(76%)和肝(48%)。
  • 米托坦启动至首次化疗的中位时间为9个月(IQR 4-18个月)。
  • 中位PFS1为6.0个月(95%CI 4.5-8.6),中位OS为46个月(95%CI 41-68)。
  • 米托坦联合LRT组较单用米托坦组的PFS1、PFS2和OS均显著更长,HR分别为0.39(95%CI 0.22-0.68)、0.35(95%CI 0.20-0.63)和0.27(95%CI 0.14-0.50)。

关键数值与推荐

  • 欧洲和法国指南推荐ENSAT IV期低肿瘤负荷或惰性ACC采用米托坦联合LRT作为一线治疗。

临床怎么用

  • 对于IVA期且受累器官≤2个的ACC患者,可考虑米托坦联合LRT作为一线治疗策略。
  • 联合治疗可能延长至首次化疗的时间并提高完全缓解率。

局限性

  • 本研究为单中心回顾性研究,样本量有限(79例)。
  • 结果需前瞻性研究进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: European and French guidelines for ENSAT stage IV low tumor burden or indolent adrenocortical carcinoma (ACC) recommend a combination of mitotane and locoregional treatments (LRT) as first-line treatment. Nevertheless, the benefit of LRT in combination with mitotane has never been evaluated in this selected group of patients. OBJECTIVE: This work aimed to evaluate the therapeutic strategy of LRT combined with mitotane in patients with low tumor burden stage IVA ACC. METHODS: A retrospective chart review was performed from 2003 to 2018 of patients with stage IV ACC with 2 or fewer tumoral organs who received mitotane in our center. The primary end point was the delay between mitotane initiation and first systemic chemotherapy. Secondary end points were progression-free survival (PFS) and overall survival (OS) from mitotane initiation. Adjusted analyses were performed on the main prognostic factors. RESULTS: Out of 79 included patients, 48 (61%) patients were female and the median age at stage IVA diagnosis was 49.8 years (interquartile range [IQR], 38.8-60.0 years). Metastatic sites were mainly lungs (76%) and liver (48%). Fifty-eight (73%) patients received LRT including adrenal bed radiotherapy (14 patients, 18%), surgery (37 patients, 47%), and/or interventional radiology (35 patients, 44%). Median time between mitotane initiation and first chemotherapy administration was 9 months (IQR, 4-18 months). Median PFS1 (first tumor-progression) was 6.0 months (95% CI, 4.5-8.6). Median OS was 46 months (95% CI, 41-68). PFS1, PFS2, and OS were statistically longer in the mitotane plus LRT group compared to the mitotane-only group (hazard ratio [HR] = 0.39; 95% CI, 0.22-0.68; HR = 0.35; 95% CI, 0.20-0.63; and HR = 0.27; 95% CI, 0.14-0.50, respectively). Ten (13%) patients achieved complete response (CR), all from the mitotane plus LRT group. CONCLUSION: Our results endorse European and French guidelines for stage IV ACC with 2 or fewer tumor organs and favor the combination of mitotane and LRT as first-line treatment. For the first time, a significant number of CRs were observed. Prospective studies are expected to confirm these findings.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Boilève A, Mathy E, Roux C, et al. Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. J Clin Endocrinol Metab. 2021. PMID: 34143888. doi:10.1210/clinem/dgab449

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。